Transactiva Inc. is a biotechnology SME, founded in 2001 by researchers with proven experience in the field of molecular biology and genetic engineering.
The company represents a R&D center of therapeutic molecules whose production cannot be carried out by chemical synthesis, thus requiring innovative biosynthetic processes.
The activities carried out by Transactiva are aimed at defining technological platforms exploitable at an industrial level for the production of therapeutic proteins in plants (molecular farming).
The ultimate objective is represented by the registration of drugs containing active ingredients obtained from genetically transformed plant tissues, accomplished through the fulfillment of partnership agreements with pharmaceutical industries.
The main activities carried out by Transactiva are:
- pharmaceutical research, with particular emphasis to the applications of recombinant DNA technology in plants;
- development of novel platforms for the synthesis, accumulation and storage of drugs in plant tissues;
- molecular farming of pharmaceutical proteins for the therapy of tumors and orphan diseases.
Transactiva works closely with large and medium pharmaceutical companies for the development, scaling-up and commercialization of molecular farming – derived biotechnological therapeutics.
Over the years Transactiva has partnered with public and private organizations active in the fields of biotechnological, pharmaceutical and agronomic research and with institutions promoting innovation and technology transfer (like universities and science parks).